Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. develops pemvidutide, a late clinical-stage dual-action therapy targeting glucagon and GLP-1 receptors for serious liver diseases. Company news centers on pemvidutide development in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), including clinical trial updates and FDA designations such as Fast Track and Breakthrough Therapy Designation where granted.
Altimmune updates also cover financial results, business updates, investor conference participation and capital actions used to fund development activity. Recurring financing news includes public offerings, registered direct offerings, common stock, pre-funded warrants and common stock warrants.
Altimmune (NASDAQ: ALT), a late clinical-stage biopharmaceutical company, has scheduled its first quarter 2025 financial results announcement for Tuesday, May 13, 2025. The company will host a conference call and webcast at 8:30 am E.T. on the same day, during which management will discuss the financial performance and provide a business update.
Investors can access the webcast through Altimmune's Investor Relations website, and participants wishing to join the call can register to receive dial-in information. A replay of the call will be available on the company's website for up to three months following the event.
Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, has announced its upcoming participation in the Citizens Life Sciences Conference. The company's management team will engage in a fireside chat scheduled for Wednesday, May 7, 2025, at 9:30 a.m. EDT.
Interested parties can access the session through a webcast available in the Events section of the Altimmune website. This participation demonstrates the company's continued engagement with the investment community and commitment to transparency in communications.
Altimmune (Nasdaq: ALT) has announced a virtual R&D Day scheduled for March 13, 2025 at 12:00 pm Eastern Time. The event will showcase presentations from Key Opinion Leaders (KOLs) focusing on multiple therapeutic areas for pemvidutide:
- Obesity treatment applications
- MASH (Metabolic Dysfunction-Associated Steatohepatitis)
- Two additional newly FDA-cleared indications
The R&D Day will cover the scientific basis for pemvidutide across these indications, review existing clinical data, and outline development strategies. A significant highlight will be discussing the upcoming topline data from the IMPACT Phase 2b trial in MASH, expected in Q2 2025. The event will be accessible through https://investorday.altimmune.com and the company's website Events section.
Altimmune (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, has announced its upcoming participation in the Leerink Global Healthcare Conference in March 2025. The company's management team will engage in a fireside chat session during the conference.
The event will be accessible via webcast through the Events section of the Altimmune website, providing investors and interested parties an opportunity to follow the discussion remotely.
Altimmune (NASDAQ: ALT) has announced its Q4 and full year 2024 financial results, highlighting significant progress in its pemvidutide development program. The company reports cash reserves of $131.9 million as of December 31, 2024.
Key developments include:
- Top-line data from Phase 2b IMPACT trial in MASH expected in Q2 2025
- FDA clearance received for two additional pemvidutide indications
- Phase 2 trials for new indications to commence mid-2025
Financial highlights for Q4 2024:
- R&D expenses: $19.8 million
- G&A expenses: $5.1 million
- Net loss: $23.2 million ($0.33 per share)
The company strengthened its Board with two pharmaceutical industry veterans and plans to hold a virtual R&D Day on March 13, 2025.
Altimmune (Nasdaq: ALT) has appointed Teri Lawver and Jerry Durso to its Board of Directors as the company advances into late-stage clinical development for pemvidutide and prepares for transition to a pre-commercial organization.
Lawver brings nearly 30 years of healthcare experience, most recently serving as Chief Commercial Officer at Dexcom where she led the launch of the industry's first over-the-counter glucose biosensor. Previously, she spent 20 years at Johnson & Johnson in senior leadership roles, including global commercial responsibility for Janssen's $16 billion immunology portfolio.
Durso has over 30 years of leadership experience, most recently as CEO of Intercept Pharmaceuticals where he built a successful rare liver disease franchise and led the company through its acquisition by Alfasigma. He previously spent over 20 years at Sanofi in various senior positions.
Both executives will help guide Altimmune's strategic vision to develop and commercialize pemvidutide, which has shown promising effects on liver defatting, weight loss, and serum lipid improvements.
Altimmune (Nasdaq: ALT) has announced it will release its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025. The clinical-stage biopharmaceutical company will host a conference call at 8:30 am E.T. on the same day, during which management will discuss financial results and provide a business update.
The conference call will be accessible through a webcast on Altimmune's Investor Relations website. Interested participants can register online to receive dial-in numbers and a unique PIN for call access. A replay of the call will be available on the company's Investor Relations website for up to three months following the event.